Department of Ophthalmology, School of Medicine, University of Colorado, Aurora, CO, USA.
Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA.
Adv Exp Med Biol. 2018;1032:173-202. doi: 10.1007/978-3-319-98788-0_13.
Aldose reductase (AR) is an NADPH-dependent aldo-keto reductase that has been shown to be involved in the pathogenesis of several blinding diseases such as uveitis, diabetic retinopathy (DR) and cataract. However, possible mechanisms linking the action of AR to these diseases are not well understood. As DR and cataract are among the leading causes of blindness in the world, there is an urgent need to explore therapeutic strategies to prevent or delay their onset. Studies with AR inhibitors and gene-targeted mice have demonstrated that the action of AR is also linked to cancer onset and progression. In this review we examine possible mechanisms that relate AR to molecular signaling cascades and thus explain why AR inhibition is an effective strategy against colon cancer as well as diseases of the eye such as uveitis, cataract, and retinopathy.
醛糖还原酶(AR)是一种 NADPH 依赖性醛酮还原酶,已被证明与几种致盲疾病的发病机制有关,如葡萄膜炎、糖尿病视网膜病变(DR)和白内障。然而,将 AR 的作用与这些疾病联系起来的可能机制尚不清楚。由于 DR 和白内障是世界上导致失明的主要原因之一,因此迫切需要探索治疗策略来预防或延迟其发病。AR 抑制剂和基因靶向小鼠的研究表明,AR 的作用也与癌症的发生和进展有关。在这篇综述中,我们研究了将 AR 与分子信号级联联系起来的可能机制,从而解释了为什么 AR 抑制是对抗结肠癌以及眼部疾病(如葡萄膜炎、白内障和视网膜病变)的有效策略。